Pular para o conteúdo
Merck
  • Development of PLGA nanoparticles for sustained release of a connexin43 mimetic peptide to target glioblastoma cells.

Development of PLGA nanoparticles for sustained release of a connexin43 mimetic peptide to target glioblastoma cells.

Materials science & engineering. C, Materials for biological applications (2020-01-12)
Rose Roberts, James W Smyth, John Will, Payton Roberts, Christina L Grek, Gautam S Ghatnekar, Zhi Sheng, Robert G Gourdie, Samy Lamouille, E Johan Foster
RESUMO

Effective therapeutic delivery of peptide and protein drugs is challenged by short in vivo half-lives due to rapid degradation. Sustained release formulations of αCT1, a 25 amino acid peptide drug, would afford lower dosing frequency in indications that require long term treatment, such as chronic wounds and cancers. In this study, rhodamine B (RhB) was used as a model drug to develop and optimize a double emulsion-solvent evaporation method of poly(lactic-co-glycolic acid) (PLGA) nanoparticle synthesis. Encapsulation of αCT1 in these nanoparticles (NPs) resulted in a sustained in vitro release profile over three weeks, characterized by an initial burst release of approximately 50% of total encapsulated drug over the first three days followed by sustained release over the remaining two and a half weeks. NP uptake by glioblastoma stem cells was through endocytosis and RhB and αCT1 were observed in cells after at least 4 days.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
Bromoacetic acid, ReagentPlus®, ≥99.0%